作者投稿
专家审稿
编辑办公
邮件订阅
RSS
Will the Strategies of Stroke Prevention Change with the New Diagnostic Standard of Hypertension?
-
摘要: 高血压是卒中最重要的危险因素。我国目前高血压控制情况不佳，高血压知晓率、治疗率和控制率均较低。2017年，美国成人高血压预防、监测、评估和管理指南更新了高血压诊断标准，将高血压阈值定为130/80 mm Hg(1 mm Hg=0.133 kPa)，并在该标准下制定了新的高血压治疗目标和管理策略。该指南主要基于收缩压干预试验(Systolic Blood Pressure Intervention Trial, SPRINT)研究结果，即与标准降压治疗相比，强化降压治疗可降低心血管事件发生率和全因死亡率。但同时，这一标准使高血压患者的数量大幅增加，且将影响大部分人群的治疗措施，包括老年人群和衰弱人群，在增加经济负担的同时增加了特殊人群的不良反应，不利于高血压防控和个体化治疗。故在此高血压标准下，结合现有证据，我国卒中预防策略尤其是一级预防应有所变化。Abstract: Hypertension is the most important risk factor for stroke, which is not well controlled in China. The rates of awareness, treatment, and control of hypertension are low. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults redefines hypertension, setting the threshold of hypertension at 130/80 mm Hg(1 mm Hg=0.133 kPa). By this standard, new therapeutic targets and management strategies for hypertension were formulated. The guideline is based on the results of Systolic Blood Pressure Intervention Trial (SPRINT), which indicate that intensive antihypertensive therapy reduces the incidence of cardiovascular events and all-cause mortality compared with the standard blood pressure control. But at the same time, this standard increases the number of patients with hypertension and affects the treatment measures in most people including the elderly and the weakened population. It increases the economic burden while increasing the adverse reactions in special populations, which is not conductive to the prevention and individualized treatment of hypertension. Therefore, by this hypertension standard, according to the existing medical evidence, it is suggested that strategies of stroke prevention, especially primary prevention, should be changed in China.
-
Key words:
- hypertension /
- guideline /
- stroke, prevention /
- antihypertension therapy
利益冲突 无 -
[1] Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ ABC/ACPM/AGS/APhA/ ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: a Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines[J]. Circulation, 2018, 138: e484-e594. https://pubmed.ncbi.nlm.nih.gov/29146533/ [2] Guo X, Zhang X, Guo L, et al. Association between pre-hypertension and cardiovascular outcomes: a systematic review and meta-analysis of prospective studies[J]. Curr Hypertens Rep, 2013, 15: 703-716. doi: 10.1007/s11906-013-0403-y [3] Huang Y, Wang S, Cai X, et al. Prehypertension and incidence of cardiovascular disease: a meta-analysis[J]. BMC Med, 2013, 11: 177. doi: 10.1186/1741-7015-11-177 [4] Lee M, Saver JL, Chang B, et al. Presence of baseline prehypertension and risk of incident stroke: a meta-analysis[J]. Neurology, 2011, 77: 1330-1337. doi: 10.1212/WNL.0b013e3182315234 [5] Shen L, Ma H, Xiang MX, et al. Meta-analysis of cohort studies of baseline prehypertension and risk of coronary heart disease[J]. Am J Cardiol, 2013, 112: 266-271. doi: 10.1016/j.amjcard.2013.03.023 [6] Wang S, Wu H, Zhang Q, et al. Impact of baseline prehypertension on cardiovascular events and all-cause mortality in the general population: a meta-analysis of prospective cohort studies[J]. Int J Cardiol, 2013, 168: 4857-4860. doi: 10.1016/j.ijcard.2013.07.063 [7] Bress AP, Kramer H, Khatib R, et al. Potential Deaths Averted and Serious Adverse Events Incurred from Adoption of the SPRINT (Systolic Blood Pressure Intervention Trial) Intensive blood pressure Regimen in the United States: Projections from NHANES (National Health and Nutrition Examination Survey)[J].Circulation, 2017, 135: 1617-1628. doi: 10.1161/CIRCULATIONAHA.116.025322 [8] Esh H, Agabiti E, France MA, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension[J]. Eur Heart J, 2018, 39: 3021-3104. doi: 10.1093/eurheartj/ehy339 [9] 《中国高血压指南》修订委员会.中国高血压防治指南2018年修订版[J].心脑血管病防治, 2019, 19: 1-45. [10] Hemphill JC 3rd, Greenberg SM, Anderson CS, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association[J]. Stroke, 2015, 46: 2032-2060. doi: 10.1161/STR.0000000000000069 [11] 中华医学会神经病学分会, 中华医学会神经病学分会脑血管病学组.中国脑出血诊治指南(2014)[J].中华神经科杂志, 2015, 48: 435-444. doi: 10.3760/cma.j.issn.1006-7876.2015.06.002 [12] Anderson CS, Huang Y, Wang JG, et al. Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trial[J]. Lancet Neurol, 2008, 7: 391-399. doi: 10.1016/S1474-4422(08)70069-3 [13] Anderson CS, Heeley E, Huang Y, et al. Rapid Blood-Pressure Lowering in Patients With Acute Intracerebral Hemorrhage[J]. N Engl J Med, 2013, 368: 2355-2365. doi: 10.1056/NEJMoa1214609 [14] Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH) investigators. Antihypertensive treatment of acute cerebral hemorrhage[J]. Crit Care Med, 2010, 38: 637-648. doi: 10.1097/CCM.0b013e3181b9e1a5 [15] Qureshi AI, Palesch YY, Barsan WG, et al. Intensive Blood-Pressure Lowering in Patients with acute Cerebral Hemorrhage[J]. N Engl J Med, 2016, 375: 1033-1043. doi: 10.1056/NEJMoa1603460 [16] Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 Guidelines for the Early Management of Patients with Acute Ischemic Stroke A Guideline for Healthcare Professionals from the American Heart Association/American Stroke Association[J]. Stroke, 2018, 49: e46-e110. doi: 10.1161/STROKEAHA.117.019582 [17] 中华医学会神经病学分会, 中华医学会神经病学分会脑血管病学组.中国急性缺血性脑卒中诊治指南2018[J].中华神经科杂志, 2018, 51: 666-682. doi: 10.3760/cma.j.issn.1006-7876.2018.09.004 [18] 中华医学会神经病学分会, 中华医学会神经病学分会脑血管病学组.中国脑卒中和短暂性脑缺血发作二级预防指南2014[J].中华神经科杂志, 2015, 48: 258-273 doi: 10.3760/cma.j.issn.1006-7876.2015.04.003 [19] Williamson JD, Supiano MA, Appleqate WB, et al. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial[J]. JAMA, 2016, 31: 2673-2682. [20] HYVET Study Group. Immediate and late benefits of treating very elderly people with hypertension: results from active treatment extension to Hypertension in the Very Elderly randomised controlled trial[J]. BMJ, 2011, 344: d7541. https://www.ncbi.nlm.nih.gov/pubmed/22218098 [21] Beckett NS, Peters R, Fletcher AE, et al. Treatment of Hypertension in Patients 80 Years of Age or Older[J]. N Engl J Med, 2008, 358: 1887-1898. doi: 10.1056/NEJMoa0801369 [22] Lu J, Lu Y, Wang X, et al. Prevalence, awareness, treatment, and control of hypertension in China: data from 1.7 million adults in a population-based screening study (China PEACE Million Persons Project)[J]. Lancet, 2017, 390: 2549-2558. doi: 10.1016/S0140-6736(17)32478-9 [23] Wang W, Jiang B, Sun H, et al. Prevalence, Incidence, and Mortality of Stroke in China: Results from a Nationwide Population-Based Survey of 480 687 Adults[J]. Circulation, 2017, 135: 759-771. doi: 10.1161/CIRCULATIONAHA.116.025250 [24] Huang Y, Cai X, Li Y, et al. Prehypertension and the risk of stroke: A meta-analysis[J]. Neurology, 2014, 82: 1153-1161. doi: 10.1212/WNL.0000000000000268 -
下载: 
点击查看大图
表(1)
计量
- 文章访问数: 472
- HTML全文浏览量: 44
- PDF下载量: 455
- 被引次数: 0
